Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The pathophysiology of lean nonalcoholic fatty liver disease (NAFLD) is unclear but has been shown to be associated with more diverse pathogenic mechanisms than that of obese NAFLD. We investigated the characteristics of genetic or metabolic lean NAFLD in a health checkup cohort. Methods: This retrospective cross-sectional study analyzed single nucleotide polymorphism data for 6,939 health examinees. Lean individuals were categorized according to a body mass index cutoff of 23 kg/m2. Single nucleotide polymorphisms were analyzed using genotyping arrays. Results: The prevalence of lean NAFLD was 21.6% among all participants with NAFLD, and the proportion of lean NAFLD was 18.5% among lean participants. The prevalence of metabolic syndrome and diabetes among lean patients with NAFLD was 12.4% and 10.4%, respectively. Lean NAFLD appeared to be metabolic-associated in approximately 20.1% of patients. The homozygous minor allele (GG) of PNPLA3 (rs738409) and heterozygous minor alleles (CT, TT) of TM6SF2 (rs58542926) were associated with lean NAFLD. However, the prevalence of fatty liver was not associated with the genetic variants MBOAT7 (rs641738), HSD17B13 (rs72613567), MARC1 (rs2642438), or AGXT2 (rs2291702) in lean individuals. Lean NAFLD appeared to be associated with PNPLA3 or TM6SF2 genetic variation in approximately 32.1% of cases. Multivariate risk factor analysis showed that metabolic risk factors, genetic risk variants, and waist circumference were independent risk factors for lean NAFLD. Conclusions: In a considerable number of patients, lean NAFLD did not appear to be associated with known genetic or metabolic risk factors. Further studies are required to investigate additional risk factors and gain a more comprehensive understanding of lean NAFLD.
Abstract
Background/Aims: The pathophysiology of lean nonalcoholic fatty liver disease (NAFLD) is unclear but has been shown to be associated with more diverse pathogenic mechanisms than that of obese NAFLD. We investigated the characteristics of genetic or metabolic lean NAFLD in a health checkup cohort. Methods: This retrospective cross-sectional study analyzed single nucleotide polymorphism data for 6,939 health examinees. Lean individuals were categorized according to a body mass index cutoff of 23 kg/m2. Single nucleotide polymorphisms were analyzed using genotyping arrays. Results: The prevalence of lean NAFLD was 21.6% among all participants with NAFLD, and the proportion of lean NAFLD was 18.5% among lean participants. The prevalence of metabolic syndrome and diabetes among lean patients with NAFLD was 12.4% and 10.4%, respectively. Lean NAFLD appeared to be metabolic-associated in approximately 20.1% of patients. The homozygous minor allele (GG) of PNPLA3 (rs738409) and heterozygous minor alleles (CT, TT) of TM6SF2 (rs58542926) were associated with lean NAFLD. However, the prevalence of fatty liver was not associated with the genetic variants MBOAT7 (rs641738), HSD17B13 (rs72613567), MARC1 (rs2642438), or AGXT2 (rs2291702) in lean individuals. Lean NAFLD appeared to be associated with PNPLA3 or TM6SF2 genetic variation in approximately 32.1% of cases. Multivariate risk factor analysis showed that metabolic risk factors, genetic risk variants, and waist circumference were independent risk factors for lean NAFLD. Conclusions: In a considerable number of patients, lean NAFLD did not appear to be associated with known genetic or metabolic risk factors. Further studies are required to investigate additional risk factors and gain a more comprehensive understanding of lean NAFLD.
참고문헌 (33)
- Younossi ZM, "Epidemiology of chronic liver diseases in the USA in the past three decades", Gut, 69, pp.564~568 (2020)
- Sookoian S, "Systematic review with meta-analysis : risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients", Aliment Pharmacol Ther, 46, pp.85~95 (2017)
- Sookoian S, "Genetic predisposition in nonalcoholic fatty liver disease", Clin Mol Hepatol, 23, pp.1~12 (2017)
- Vilarinho S, "Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD", Hepatology, 74, pp.2241~2250 (2021)
- Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
- Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
- Mancina RM, "The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent", Gastroenterology, 150, pp.1219~1230 (2016)
- Ma Y, "17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease", Hepatology, 69, pp.1504~1519 (2019)
- Luukkonen PK, "MARC1variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans", J Hepatol, 73, pp.725~726 (2020)
- Yoo T, "Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease", J Hepatol, 75, pp.514~523 (2021)
- Honda Y, "Characteristics of nonobese non-alcoholic fatty liver disease : effect of genetic and environmental factors", Hepatol Res, 46, pp.1011~1018 (2016)
- Sugiura T, "Serum levels of Mac-2binding protein increase with cardiovascular risk and reflect silent atherosclerosis", Atherosclerosis, 251, pp.192~196 (2016)
- Lee C, "Health and Prevention Enhancement(H-PEACE) : a retrospective, populationbased cohort study conducted at the Seoul National University Hospital Gangnam Center, Korea", BMJ Open, 8, pp.e019327~ (2018)
- McPherson S, "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)
- "Guidelines for data processing and analysis of the IPAQ-short and long forms" (2022)[URL]
- Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
- Oh SW, "Obesity and metabolic syndrome in Korea", Diabetes Metab J, 35, pp.561~566 (2011)
- Chahal D, "Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank", Hepatol Int, 16, pp.325~336 (2022)
- Francque S, "NAFLD in lean individuals : not a benign disease", Gut, 71, pp.234~236 (2022)
- Park H, "Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease", Gut, 71, pp.1035~1036 (2022)
- Chon YE, "Hepatocellular carcinoma statistics in South Korea", Clin Mol Hepatol, 27, pp.512~514 (2021)
- Lin H, "Association of genetic variations with NAFLD in lean individuals", Liver Int, 42, pp.149~160 (2022)
- Pennisi G, "PNPLA3 rs738409C>G variant predicts fibrosis progression by noninvasive tools in nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 19, pp.1979~1981 (2021)
- Vilar-Gomez E, "PNPLA3 rs738409 and risk of fibrosis in NAFLD : exploring mediation pathways through intermediate histological features", Hepatology, 76, pp.1482~1494 (2022)
- Koo BK, "Long-term effect of PNPLA3 on the aggravation of nonalcoholic fatty liver disease in a biopsy-proven cohort", Clin Gastroenterol Hepatol, 21, pp.1105~1107 (2023)
- Luo F, "TM6SF2 : a novel genetic player in nonalcoholic fatty liver and cardiovascular disease", Hepatol Commun, 6, pp.448~460 (2022)
- Kahali B, "TM6SF2 : catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?", Gastroenterology, 148, pp.679~684 (2015)
- Yuan L, "PNPLA3 and nonalcoholic fatty liver disease : towards personalized medicine for fatty liver", Hepatobiliary Surg Nutr, 9, pp.353~356 (2020)
- Kim D, "Association between body sizemetabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis", J Gastroenterol, 55, pp.330~341 (2020)
- Kim D, "Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease", Liver Int, 39, pp.332~341 (2019)
- Jang H, "Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?", Clin Mol Hepatol, 29, pp.381~383 (2023)
- Chan WK, "Comparison between obese and non-obese nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S58~S67 (2023)
- Rochlani Y, "Metabolic syndrome : pathophysiology, management, and modulation by natural compounds", Ther Adv Cardiovasc Dis, 11, pp.215~225 (2017)